CLINICAL_TRIALS ClinicalTrials.gov record update

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02506959
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:43.883114+00:00
Published At: 2025-03-18T00:00:00+00:00
Record Updated At: 2025-03-18
Results Posted At: 2025-03-18
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Plasma Cell Leukemia", "Plasmacytoma", "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-03-18"
protocolSection.identificationModule.nctId: "NCT02506959"
protocolSection.identificationModule.officialTitle: "Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-03-18"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.